Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.

In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, outcome of human cytomegalovirus (HCMV) infection results from balance between viral load/replication and pathogen-specific T-cell response. Using a cut-off of 30,000 HCMV DNA copies/ml blood for pre-emptive therapy and cut-off...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daniele Lilleri, Giuseppe Gerna, Paola Zelini, Antonella Chiesa, Vanina Rognoni, Angela Mastronuzzi, Giovanna Giorgiani, Marco Zecca, Franco Locatelli
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2012
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/77a56ab237794f48bd4b18e32b10a1f1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:77a56ab237794f48bd4b18e32b10a1f1
record_format	dspace
spelling	oai:doaj.org-article:77a56ab237794f48bd4b18e32b10a1f12021-11-18T07:11:05ZMonitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.1932-620310.1371/journal.pone.0041648https://doaj.org/article/77a56ab237794f48bd4b18e32b10a1f12012-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/22848556/?tool=EBIhttps://doaj.org/toc/1932-6203In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, outcome of human cytomegalovirus (HCMV) infection results from balance between viral load/replication and pathogen-specific T-cell response. Using a cut-off of 30,000 HCMV DNA copies/ml blood for pre-emptive therapy and cut-offs of 1 and 3 virus-specific CD4(+) and CD8(+) T cells/µl blood for T-cell protection, we conducted in 131 young patients a prospective 3-year study aimed at verifying whether achievement of such immunological cut-offs protects from HCMV disease. In the first three months after transplantation, 55/89 (62%) HCMV-seropositive patients had infection and 36/55 (65%) were treated pre-emptively, whereas only 7/42 (17%) HCMV-seronegative patients developed infection and 3/7 (43%) were treated. After 12 months, 76 HCMV-seropositive and 9 HCMV-seronegative patients (cumulative incidence: 90% and 21%, respectively) displayed protective HCMV-specific immunity. Eighty of these 85 (95%) patients showed spontaneous control of HCMV infection without additional treatment. Five patients after reaching protective T-cell levels needed pre-emptive therapy, because they developed graft-versus-host disease (GvHD). HSCT recipients reconstituting protective levels of HCMV-specific T-cells in the absence of GvHD are no longer at risk for HCMV disease, at least within 3 years after transplantation. The decision to treat HCMV infection in young HSCT recipients may be taken by combining virological and immunological findings.Daniele LilleriGiuseppe GernaPaola ZeliniAntonella ChiesaVanina RognoniAngela MastronuzziGiovanna GiorgianiMarco ZeccaFranco LocatelliPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 7, Iss 7, p e41648 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Daniele Lilleri Giuseppe Gerna Paola Zelini Antonella Chiesa Vanina Rognoni Angela Mastronuzzi Giovanna Giorgiani Marco Zecca Franco Locatelli Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
description	In allogeneic hematopoietic stem-cell transplantation (HSCT) recipients, outcome of human cytomegalovirus (HCMV) infection results from balance between viral load/replication and pathogen-specific T-cell response. Using a cut-off of 30,000 HCMV DNA copies/ml blood for pre-emptive therapy and cut-offs of 1 and 3 virus-specific CD4(+) and CD8(+) T cells/µl blood for T-cell protection, we conducted in 131 young patients a prospective 3-year study aimed at verifying whether achievement of such immunological cut-offs protects from HCMV disease. In the first three months after transplantation, 55/89 (62%) HCMV-seropositive patients had infection and 36/55 (65%) were treated pre-emptively, whereas only 7/42 (17%) HCMV-seronegative patients developed infection and 3/7 (43%) were treated. After 12 months, 76 HCMV-seropositive and 9 HCMV-seronegative patients (cumulative incidence: 90% and 21%, respectively) displayed protective HCMV-specific immunity. Eighty of these 85 (95%) patients showed spontaneous control of HCMV infection without additional treatment. Five patients after reaching protective T-cell levels needed pre-emptive therapy, because they developed graft-versus-host disease (GvHD). HSCT recipients reconstituting protective levels of HCMV-specific T-cells in the absence of GvHD are no longer at risk for HCMV disease, at least within 3 years after transplantation. The decision to treat HCMV infection in young HSCT recipients may be taken by combining virological and immunological findings.
format	article
author	Daniele Lilleri Giuseppe Gerna Paola Zelini Antonella Chiesa Vanina Rognoni Angela Mastronuzzi Giovanna Giorgiani Marco Zecca Franco Locatelli
author_facet	Daniele Lilleri Giuseppe Gerna Paola Zelini Antonella Chiesa Vanina Rognoni Angela Mastronuzzi Giovanna Giorgiani Marco Zecca Franco Locatelli
author_sort	Daniele Lilleri
title	Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
title_short	Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
title_full	Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
title_fullStr	Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
title_full_unstemmed	Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
title_sort	monitoring of human cytomegalovirus and virus-specific t-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.
publisher	Public Library of Science (PLoS)
publishDate	2012
url	https://doaj.org/article/77a56ab237794f48bd4b18e32b10a1f1
work_keys_str_mv	AT danielelilleri monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT giuseppegerna monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT paolazelini monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT antonellachiesa monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT vaninarognoni monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT angelamastronuzzi monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT giovannagiorgiani monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT marcozecca monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation AT francolocatelli monitoringofhumancytomegalovirusandvirusspecifictcellresponseinyoungpatientsreceivingallogeneichematopoieticstemcelltransplantation
_version_	1718423796761755648

Monitoring of human cytomegalovirus and virus-specific T-cell response in young patients receiving allogeneic hematopoietic stem cell transplantation.

Ejemplares similares